Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...
Free to browse, no account needed Track IBIO with free AI briefings, catalyst countdowns, and dilution alerts.

IBIO · iBio, Inc.

Company guidance, FDA catalysts, dilution risk and cash runway, built from SEC, FDA and ClinicalTrials.gov filings and updated every day.

$76.7M Cash on Hand
29.5mo Cash Runway
Follow IBIO by email Get an email when IBIO reports key news in an SEC filing, pushes back a promised milestone, files for a stock offering, lands on the Downside Radar or has an FDA decision. Free, no account needed.

We send one confirmation email first. Only emails about IBIO, unsubscribe in one click. Privacy

📣 What IBIO Says Is Next

Quoted word for word from the company's press releases filed with the SEC. Timing is the company's own guidance, not a BioRadar estimate.

📄 Latest SEC Filings in Plain English

Each summary is written by AI from the filing itself, and one that names a number or a name the filing does not contain is not shown. Quarterly and annual reports are listed by period. Read the filing before acting on it.

🧪 Trial & FDA Catalysts

📊 Drug Pipeline

DrugIndicationMost advanced trialStatus
IBIO-600 Overweight , Obesity Phase 1 · NCT07487376 Recruiting
IBIO-610 Obesity & Overweight Phase 1 · NCT07890870 Not yet recruiting
Lasmotinib (PHI-101) Relapsed or Refractory Acute Myeloid Leukemia Phase 1 · NCT04842370 Unknown

Source: ClinicalTrials.gov trials sponsored by the company, one row per candidate at its most advanced registered trial. FDA approvals: Drugs@FDA. Wrong or missing drug? Report it

💰 Cash Runway & Dilution Risk

IBIO holds $76.7M in cash and short-term investments (as of Sep 30, 2026) and burns about $7.8M/quarter from operations, an estimated runway of 29.5 months at that rate (BioRadar estimate, not company guidance).

Dilution pressure: 35 · Moderate

Recent financing filings on SEC EDGAR:

Source: SEC EDGAR (XBRL cash flow and financing filings). Dilution Watch: every company ranked → · Get an alert when IBIO files for a raise →

👥 Who Owns IBIO

Insiders 0.4% Other 5%+ holders 5.7% Institutions (72 holders) 62.1% Public and other holders 31.8%
HolderTypeShares% of sharesAs of
Sirenia Capital Management LP Institution (13G, 5%+) 11,586,340 16.44% 2026-03-31
Coastlands Capital LP Institution (13G, 5%+) 6,247,738 8.87% 2026-10-07
Cormorant Asset Management, LP Institution (13G, 5%+) 5,117,481 7.26% 2026-06-30
Affinity Asset Advisors, LLC Institution (13G, 5%+) 5,068,882 7.19% 2026-06-30
Vestal Point Capital, LP Institution (13G, 5%+) 4,025,000 5.71% 2026-06-30
Lynx1 Capital Management LP 5%+ holder (13G) 2,807,016 3.98% 2026-06-30
Millennium Management LLC 5%+ holder (13G) 1,235,827 1.75% 2026-01-15
Antonio Bernardino Guimaraes Parada
Director · +64,100 options
Insider 183,823 0.26% 2025-01-10
Felipe Duran
Chief Financial Officer · +428,700 options
Insider 35,974 0.05% 2026-03-19
Martin Brenner
Chief Executive Officer and Chief Scient · +999,700 options
Insider 30,652 0.04% 2026-03-19
Marc Banjak
Chief Legal Officer · +272,000 options
Insider 25,000 0.04% 2026-03-26
David Arkowitz
Director · +64,100 options
Insider 18,382 0.03% 2025-01-10

Share count 70,455,809 (latest 10-Q/10-K). Insiders: each officer's, director's and 10% owner's latest Form 3, 4 or 5, direct and indirect shares; options are not counted. 5%+ holders: latest Schedule 13D or 13G of each holder above 5%. Institutions: the total held by all 13F filers (Yahoo Finance); the table lists the largest. Sources have different dates, so the split is approximate. Source: SEC EDGAR.

Get the full IBIO picture

The 7-day free trial adds AI daily briefings, sentiment tracking, trial enrollment progress and email alerts for IBIO and every other ticker you follow. Card required, cancel anytime.

Start 7-day free trial →

Data: SEC EDGAR, FDA, ClinicalTrials.gov, Yahoo Finance • Informational purposes only, not investment advice. • All tracked stocks A–Z

This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.